General MedicationsINJECTIONGeneric
IVADANTIN
NITROFURANTOIN SODIUM
Standard Dose
EQ 180MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview IVADANTIN is listed in Drugs@FDA under application 012402 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient NITROFURANTOIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 180MG BASE/VIAL Sponsor PROCTER AND GAMBLE Submission history Latest submission status date: 1982-10-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview IVADANTIN is listed in Drugs@FDA under application 012402 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NITROFURANTOIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 180MG BASE/VIAL Sponsor PROCTER AND GAMBLE Submission history Latest submission status date: 1982-10-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.